| Identification | Back Directory | [Name]
DWP14012 hydrochloride | [CAS]
1902954-87-3 | [Synonyms]
DWP14012 hydrochloride
Abeprazan hydrochloride | [Molecular Formula]
C19H18ClF3N2O3S | [MDL Number]
MFCD34469942 | [MOL File]
1902954-87-3.mol | [Molecular Weight]
446.87 |
| Hazard Information | Back Directory | [Biological Activity]
Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1].
The mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1].
Abeprazan hydrochloride (DWP14012 hydrochloride) inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1]. | [storage]
-20°C, away from moisture | [References]
[1]. Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218. |
|
|